Lyophilisates for drug delivery in ophthalmology: Pharmacokinetics of fluorescein in the human anterior segment

British Journal of Ophthalmology

Volumn 86, Issue 10, 2002, Pages 1114-1117

  Dinslage, S ^a   Diestelhorst, Michael ^a   Weichselbaum, A ^b   Suverkrup R ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCEIN; HYDROXYPROPYLMETHYLCELLULOSE; TETRAFLUOROETHYLENE;

ARTICLE; CLINICAL TRIAL; CONJUNCTIVA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORNEA; DRUG BIOAVAILABILITY; DRUG PENETRATION; DRUG UPTAKE; FLUOROPHOTOMETRY; FREEZE DRYING; HUMAN; HUMAN EXPERIMENT; LYOPHILISATE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTERIOR CHAMBER; AREA UNDER CURVE; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, CORNEAL; FEMALE; FLUORESCEIN; FREEZE DRYING; HUMANS; LENS, CRYSTALLINE; MALE; TEARS;

EID: 0036784433     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.86.10.1114     Document Type: Article

References (29)

1. Burstein NL. Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol 1980;25:15-30.
2. Gasset AR, Ishii MD, Kaufmann HE, et al. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 1977;78:98-105.
3. Khalili M, Diestelhorst M, Krieglstein GK. Long-term follow-up of 700 trabeculectomies. Klin Monatsbl Augenheilkd 2000;217:1-8.
4. Fraunfelder FT. Drugs used primarily in ophthalmology. In: Drug-induced ocular side effects. 4th ed. Baltimore: William and Wilkins, 1996:420-33.
5. Alani SD. The ophthalmic rod: a new ophthalmic drug delivery system. Graefes Arch Clin Exp Ophthalmol 1990;228:297-301.
6. Diestelhorst M, Krieglstein GK. The ocular tolerability of a new ophthalmic drug delivery system (NODS). Int Ophthalmol 1994;18:1-4.
7. Shell JW. Ophthalmic drug delivery systems. Drug Dev Res 1984;6:245-61.
8. Le Bourlais C, Acar L, Zia H, et al. Ophthalmic drug delivery systems - recent advances. Prog Ret Eye Res 1998;17:33-58.
9. Maurice DM, Mishima S. Ocular pharmacokinetics. In: Sears ML, ed. Pharmacology of the eye: handbook of experimental pharmacology. New York: Springer, 1984:69.
10. Zaki I, Fitzgerald P, Hardy JG, et al. A comparison of the effect of viscosity on the pre-corneal residence of solutions in rabbit and man. J Pharm Pharmacol 1986;38:463.
11. Kessler C, Bleckmann H, Kleintges G. Influence of the strength, drop size and viscosity of metipranolol eye drops on the concentration of the substance in human aqueous humour. Graefes Arch Clin Exp Ophthalmol 1991;229:452-6.
12. Mishima S. Clinical pharmacokinetics of the eye. Proctor lecture. Invest Ophthalmol 1981;21:504.
13. Schoenwald RD. Ocular pharmacocinetics/pharmacodynamics. In: Mitra AK, ed. Ophthalmic drug delivery systems. New York: Marcel Dekker, 1993.
14. Lederer CM, Harold RE. Drop size of commercial glaucoma medications. Am J Ophthalmol 1986;101:691-4.
15. Brown RH, Lynch MG. Drop size of commercial glaucoma medications [letter]. Am J Ophthalmol 1986;102:673-4.
16. Charap AD, Shin DH, Petursson G, et al. The effect of varying drop size on the efficacy and safety of a topical beta-blocker. Ann Ophthalmol 1988;21:351-7.
17. Mishima S, Gasser A, Klyce SD, et al. Determination of tear volume and tear flow. Invest Ophthalmol 1966;5:264-76.
18. Patton TF, Franceur M. Ocular biovailability and systemic loss of topically applied ophthalmic drugs. Am J Ophthalmol 1978;85:225.
19. Chrai SS, Makoid MC, Eriksen SP, et al. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974;63:333.
20. Farris RL, Stuchell RN, Mandell ID. Basal and reflex human tear analysis. I Physical measurements: osmolarity, basal volumes, and reflex flow rate. Am Acad Ophthal 1981;88:852.
21. Burstein NL. Comeal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol 1980;29:15-30.
22. Gasset AR, Ishii Y, Kaufman HE, et al. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 1974;78:98-105.
23. De Saint JM, Brignole F, Bringuier AF, et al. Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest Ophthalmol Vis Sci 1999;40:619-30.
24. De Saint JM, Debbasch C, Brignole F, et al. Toxicity of preserved and unpreserved beta-blocker eyedrops in an in vitro model of human conjunctival cells. J Fr Ophtalmol 2000;23:111-21.
25. Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999;106:556-63.
26. Becquet F, Goldschild M, Moldovan MS, et al. Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res 1998;17:419-25.
27. Broadway DC, Grierson I, OBrien C, et al. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994;112:1437-45.
28. Nuzzi R, Finazzo C, Cerruti A. Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lacrymal response. Int Ophthalmol 1998;22:31-5.
29. Diestelhorst M, Grunthal S, Süverkrüp R. Dry drops: a new preservative-free drug delivery system. Graefes Arch Clin Exp Ophthalmol 1999;237:394-8.